

A multi-centred randomised study of parotid sparing intensity modulated radiotherapy (IMRT) to reduce xerostomia and increase quality of life in head and neck cancer

Submission date 15/10/2002	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 15/10/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 29/10/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-at-a-new-method-of-radiotherapy-versus-standard-radiotherapy-for-head-and-neck-cancers>

Contact information

Type(s)

Scientific

Contact name

Dr Chris Nutting

Contact details

Head and Neck Unit
Royal Marsden NHS Foundation Trust
London
United Kingdom
SW3 6JJ
+44(0) 20 7352 8171
Chris.nutting@rmh.nhs.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00081029

Protocol serial number

Parotid Sparing IMRT

Study information

Scientific Title

A multi-centred randomised study of parotid sparing intensity modulated radiotherapy (IMRT) to reduce xerostomia and increase quality of life in head and neck cancer

Acronym

PARSPORT

Study objectives

Added 30 July 2008:

To determine in a randomised controlled trial the potential of intensity-modulated radiotherapy (IMRT) to reduce xerostomia and increase quality of life in head and neck cancer patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 30 July 2008: South West MREC (03/6/79) - approved 11/11/2003.

Primary study design

Interventional

Study design

Multi-centred randomised study

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Head and Neck cancer

Interventions

Patients are randomised to receive either conventional radiotherapy or parotid-sparing IMRT

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Added 30 July 2008:

The primary endpoint is the proportion of patients suffering xerostomia of grade 2 or more, assessed by the subjective measure on the LENT/SOMA late toxicity scale, one year after treatment.

Key secondary outcome(s)

Added 30 July 2008:

Secondary endpoints include:

1. Degree of xerostomia by quantitative measurements of stimulated and unstimulated salivary flow
2. Xerostomia related quality of life as measured by modified Xerostomia Questionnaire
3. Quality of life measured by the EORTC QLQ C30 v.3.0 and QLQ-H&N35 questionnaires
4. Local and regional tumour control (a quantitative description of sites of relapse will be performed)
5. Time to tumour progression and overall survival
6. Acute and late side effects of radiotherapy (NCI CTCAE scale v3.0, for acute side effects and LENT SOMA and RTOG late radiotherapy scoring systems)

Completion date

31/01/2008

Eligibility

Key inclusion criteria

1. Histologically confirmed squamous cell or undifferentiated carcinoma of the head and neck
2. Tumour arising from the oro-pharynx requiring radical radiation of the primary tumour by parallel opposed lateral fields and bilateral cervical lymph node irradiation. High risk of radiation induced xerostomia with conventional radiotherapy due to irradiation of the majority of both parotid glands. Radiotherapy either as the primary treatment or post-operative (adjuvant irradiation). Neoadjuvant chemotherapy is permitted.
3. All patients must be suitable to attend regular follow-up and undergo QoL and salivary measurements. Stage T1-4, N1-3, M0 disease. Zubrod performance status 0-1.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Total final enrolment

94

Key exclusion criteria

Added 30 July 2008:

1. Previous radiotherapy to the head and neck region
2. Previous malignancy except non-melanoma skin cancer
3. Pre-existing salivary gland pathology interfering with saliva production
4. Previous or concurrent illness which in the investigators opinion would interfere with either completion of therapy or follow-up
5. Patients with bilateral N3 nodal disease or huge primary tumour (exceeding 10cm in diameter)

6. Prophylactic use of amifostine or pilocarpine is not allowed
7. Concomitant chemotherapy is not permitted
8. Brachytherapy is not allowed as part of the treatment
9. Presence of contralateral lymphadenopathy adjacent to or involving contralateral parotid gland making parotid sparing impossible
10. Tumour of base of tongue where sparing of contralateral parapharyngeal space is contraindicated

Date of first enrolment

01/01/2003

Date of final enrolment

31/01/2008

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Head and Neck Unit

London

United Kingdom

SW3 6JJ

Sponsor information

Organisation

The Institute of Cancer Research (UK)

ROR

<https://ror.org/043jzw605>

Funder(s)

Funder type

Research organisation

Funder Name

Cancer Research UK (CRUK) (UK)

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	parotid-sapring intensity results	01/02/2011		Yes	No
Protocol article	protocol	01/10/2007		Yes	No
Other publications	pre-trial quality assurance processes	01/07/2009		Yes	No
Other publications	dosimetry audit	01/10/2009		Yes	No
Plain English results		08/11/2011	29/10/2021	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes